clinical trial · NCT07798375
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
Everest Medicines (China) Co.,Ltd.·phase2·not yet recruiting·n = 244
Neovascular Age Related Macular Degeneration(nAMD)VIS-101 6.0mg Low concentrationVIS-101 6.0mg High concentrationVIS-101 9.0mg High concentrationAflibercept (Eylea)
brief summary
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)
started
Nov 1, 2026
primary completion
Jul 1, 2028
completion
Dec 1, 2028
last updated
Nov 5, 2026
official title
A Multicenter, Randomized, Quadruple-Masked, Active-Controlled Phase 2b Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of VIS-101 Intravitreal Injection in Treatment- Naïve Participants With Neovascular Age-Related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol